Grossman Adam S 4

What Happened
Adam S. Grossman, President, CEO and a director of ADMA Biologics (ADMA), had 54,858 shares withheld on February 26, 2026 to satisfy mandatory tax withholding upon the vesting of restricted stock units (RSUs). The withholding was reported at $15.18 per share, totaling approximately $832,744. This was a tax-withholding settlement, not an open-market sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (filed within the required two-business-day window).
• Transaction code: F — shares withheld to satisfy tax withholding on RSU vesting (not a sale).
• Withheld: 54,858 shares at $15.18/share; value ≈ $832,744.
• Shares owned after transaction (reported): 1,092,470 shares of common stock (reflects prior purchases and net settlements).
• Unvested RSUs reported (selected):
  • 282,529 unvested RSUs granted Feb 9, 2026 (vests quarterly over 4 years)
  • 189,017 unvested of 252,022 RSUs granted Feb 19, 2025
  • 278,864 unvested of 557,728 RSUs granted Feb 26, 2024
  • 286,848 unvested of 573,695 RSUs granted Mar 6, 2023
  • 75,000 unvested of 300,000 RSUs granted Mar 7, 2022
• Entity holdings: Some reported shares are held by Areth, LLC and Hariden, LLC; Grossman is a control person/managing member of those entities (see footnotes).

Context
This was a routine tax-withholding event tied to RSU vesting (transaction code F). Because shares were withheld to cover taxes, it should not be read as a typical insider sale or change in investment sentiment.